This study is designed to evaluate the effectiveness and safety of an investigational medication called Itacitinib. The study is for men and women with moderate to severe Ulcerative Colitis. Itacitinib is a type of drug c alled a Janus kinase (JAK) inhibitor. Itacitinib targets proteins involved in inflammation and may reduce their production.
If you participate, you will be in the study for up to 60 weeks and will come for approximately 19 clinic visits. Participants will have a 66% chance of recieving the active investigational medication (33% will receive a placebo or dummy medication) during the first 12 weeks. After the first 12 weeks, all participants will receive the actual investigational medication.
There is no cost to participate and compensation of up to $1,500.00 is available for time and travel costs.
To be eligible to participate, you must:
1. Be between 18 and 74 years of age
2. Have a diagnosis of Ulcerative Colitis
3. Have current symptoms of Ulcerative Colitis
4. Be taking prescriptions medications for your Ulcerative Colitis